On the use of magnitude of reduction in HIV-1 RNA in clinical trials: Statistical analysis and potential biases

Journal of Acquired Immune Deficiency Syndromes

Volumn 30, Issue 1, 2002, Pages 59-64

  Flandre, Philippe ^a   Durier, Christine ^a   Descamps, Diane ^a   Launay, Odile ^a   Joly, Véronique ^a  

^a INSERM   (France)

Author keywords

Antiretroviral therapy; Censoring; HIV 1 RNA levels; Limit of quantification

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

ARTICLE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; REDUCTION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; VIROLOGY;

EID: 0036571265     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-200205010-00007     Document Type: Article

References (16)

1. Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection
2. Comparative antiviral activity and toxicity of nevirapine (NVP) versus lamivudine (3TC), in combination with stavudine (d4T) and indinavir (IDV), for the treatment of HIV-1 infected patients
3. Similar efficacy of AZT and d4T in combination with 3TC and IDV in the treatment of HIV-infected patients previously exposed to nucleosides but naive for 3TC, d4T and proteases inhibitors
4. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: Selection of thymidine analog regimen therapy (START II)
5. Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: Results of Adult AIDS Clinical Trials Group protocol 370
6. Clinical trial using HIV-1 RNA-based primary endpoints: Statistical analysis and potential biases
7. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy
8. Time of initiation of anti-retroviral therapy: Impact on HIV-1 viraemia
9. Prevalence and predictive value of intermittent viremia with combination HIV therapy
10. A nonidentifiability aspect of the problem of competing risks
11. Bounds for a joint distribution function with fixed subdistributions function: Applications to competing risks
12. A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside nalogues and indinavir for previously untreated HIV-1 infection; the OzCombol study
13. + lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure
14. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1 infected patients
15. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy
16. An open-label randomized trial to evaluate different therapeutic strategies of combination therapy in HIV-1 infection: Design, rationale, and methods of the Initio trial